Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Second generation, B-domain deleted recombinant factor VIII

E Berntorp1

  • 1Department for Coagulation Disorders, University of Lund, University Hospital, Malmö, Sweden. erlk.berntorp@medforsk.mas.lu.se

Thrombosis and Haemostasis
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Fifth Åland Island conference on von Willebrand disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Replacement therapy during surgery in von Willebrand disease needs personalization.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Defining extended half-life rFVIII-A critical review of the evidence.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Immune tolerance induction: What have we learned over time?

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same journal

Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for Atrial Fibrillation: Meta-analysis of Randomized Clinical Trials.

Thrombosis and haemostasis·2026
Same journal

Novel/Recurrent Variants in Pakistani Glanzmann Thrombasthenia and Glanzmann-like bleeding diathesis: Insights from NGS Analysis.

Thrombosis and haemostasis·2026
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
See all related articles

A novel recombinant factor VIII (r-VIII SQ) shows excellent efficacy and safety in clinical trials for hemophilia care. This albumin-free, B-domain-deleted product offers high specific activity and potential cost benefits.

Area of Science:

  • Biotechnology
  • Hematology
  • Recombinant Protein Therapeutics

Background:

  • Hemophilia A treatment relies on factor VIII (FVIII) replacement therapy.
  • Plasma-derived FVIII carries risks of viral contamination and allergic reactions.
  • Recombinant FVIII products aim to improve safety and availability.

Purpose of the Study:

  • To evaluate the safety and efficacy of a second-generation B-domain-deleted recombinant factor VIII (r-VIII SQ).
  • To assess the pharmacokinetic properties and clinical performance of r-VIII SQ.
  • To compare r-VIII SQ with existing plasma-derived and recombinant FVIII products.

Main Methods:

  • Clinical trials involving previously treated, previously untreated, and surgical patients.
  • Assessment of efficacy, safety, and pharmacokinetic profiles.

Related Experiment Videos

  • Analysis of product-specific activity, stability, and formulation.

    • Main Results:

    • r-VIII SQ demonstrates excellent efficacy and safety in over 179 patients.
    • High specific activity (15,000 IU VIII:C/mg protein) and satisfactory stability.
    • Pharmacokinetic properties are comparable to monoclonal purified plasma-derived FVIII.

    Conclusions:

    • B-domain-deleted recombinant factor VIII (r-VIII SQ) shows potential for improved convenience and cost-benefit in hemophilia care.
    • The albumin-free formulation offers a potentially better safety margin regarding viral and protein contaminants.
    • Further experience is needed, particularly concerning inhibitor development risk.